Baird lowered the firm’s price target on Haemonetics (HAE) to $72 from $87 and keeps an Outperform rating on the shares. The firm updated its model following its messy Q1 results which beat on weak IVT; but offsets should keep the 2026 guidance in check.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Barrington lowers Haemonetics price target, says pullback ‘too much’
- Haemonetics price target lowered to $70 from $90 at Mizuho
- Haemonetics Reports Q1 Fiscal 2026 Earnings
- Haemonetics downgraded to Neutral from Overweight at JPMorgan
- Haemonetics: Strong Plasma Performance and Growth in Blood Management Justify Buy Rating Despite Interventional Challenges